DECNUPAZ (Pivekimab Sunirine-pvzy) Injection

DECNUPAZ (pivekimab sunirine-pvzy), from AbbVie, is a CD123-directed antibody-drug conjugate indicated for adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive blood cancer with features of both leukemia and lymphoma.

Pivekimab sunirine targets CD123, a protein highly expressed on BPDCN cells. The antibody component delivers a cytotoxic alkylating agent (a DNA-damaging payload) directly to CD123-expressing tumor cells. Approved May 27, 2026 — verify current label wording against the live USPI before relying on trial statistics.

• Capillary leak syndrome has been associated with CD123-targeted therapies in this class — monitor for fluid retention, hypotension, and edema.
• Infusion-related reactions can occur.
• Myelosuppression (low blood counts) requires regular monitoring.
• Common side effects: fatigue, nausea, peripheral edema, decreased blood counts, infusion-related reactions.

What documents are required to import DECNUPAZ to India?

DECNUPAZ may be imported in the patient’s name only, by patients or government hospitals. The following documentation is required:

• A valid prescription from a registered hemato-oncologist
• Diagnostic/pathology report confirming BPDCN with CD123 expression
• Patient ID proof (issued by the Government of India)

How is the order confirmed?

The order is confirmed only after receipt and verification of a valid prescription and an import permit, if applicable.

Is DECNUPAZ available in India?

DECNUPAZ is not commercially marketed in India. It can be legally accessed through the Named Patient Program (NPP).

Indian Pharma Network (IPN) can source DECNUPAZ from AbbVie’s authorized distribution network and facilitate supply to patients, doctors, and hospitals. DECNUPAZ requires cold-chain handling (refrigerated 2-8°C); IPN uses temperature-monitored logistics for every shipment.

For DECNUPAZ cost in India and availability, contact IPN at Phone: +91-9310090915 or email info@indianpharmanetwork.in.

Global Approval Status:

• United States: Approved by the FDA — May 27, 2026.

What is DECNUPAZ used for?

DECNUPAZ treats blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra-rare and aggressive blood cancer, in adults.

Who manufactures DECNUPAZ?

DECNUPAZ is manufactured by AbbVie Inc.

Is DECNUPAZ FDA approved?

Yes, approved by the US FDA on May 27, 2026.

How much does DECNUPAZ cost in India?

Cost depends on body-weight dosing, sourcing logistics, and quantity — share your prescription with IPN for a quote.